Peptides and their use in diagnosis of sars-cov-2 infection
AssigneesBiotome Pty Ltd., Vivocens AB
InventorsBror Samuel LUNDIN, Ali Mohaghegh HARANDI, Alma FULURIJA
Life of this patent
Estimating the term…
Abstract
Uses and methods for diagnosing a SARS-COV-2 infection in a subject or the detection of the presence of SARS-COV-2 in a subject are provided, and which include the step of assaying a sample from the subject for the presence of antibodies that specifically bind to at least one peptide sequence derived from a linear epitope of any one or more of the S, N, or ORF1 proteins, or combinations thereof, of SARS-COV-2.
Claims19
Use of at least one peptide sequence derived from a linear epitope of the SARS-COV-2 virus, for the identification of subjects infected with SARS-COV-2.
A method of diagnosing a SARS-COV-2 infection in a subject or the detection of the presence of SARS-COV-2 in a subject, the method including the step of assaying a sample from the subject for the presence of antibodies that specifically bind to at least one peptide sequence derived from a linear epitope of any one or more of the S, N, or ORF1 proteins, or combinations thereof, of SARS-COV-2.
A diagnostic assay or kit comprising a combination of 3 or more peptides, comprising peptides comprising or consisting of any one or more of the following combinations of amino acid sequences selected from the group consisting of:
- SEQ ID NO 1 in combination with SEQ ID NO 2 and any one of SEQ ID NOS 7, 15, 18, 31, 35, 67, 113 and 139;
- and
- SEQ ID NOS 2, 74 and 128.
A diagnostic assay or kit comprising a combination of 3 or more peptides, comprising peptides comprising or consisting of any one or more of the following combinations of amino acid sequences selected from the group consisting of:
- SEQ ID NO 2 in combination with SEQ ID NO 15 and any one of SEQ ID NOS 1 or 159;
- SEQ ID NO 2 in combination with SEQ ID NOS 22 and 40;
- SEQ ID NO 2 in combination with SEQ ID NOS 22 and 128;
- SEQ ID NO 2 in combination with SEQ ID NOS 13 and 143;
- SEQ ID NO 2 in combination with SEQ ID NOS 30 and 140.
Dependencies are inferred from the claim text.